Login to Your Account



Managing Investors' Expectations

Vertex Tweaks Data Presentation, Investors React

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, July 16, 2012

For the interim analysis of its Phase II study combining VX-809 and Kalydeco (ivacaftor) in cystic fibrosis patients homozygous for the F508del mutation, Vertex Pharmaceuticals Inc. presented data pooled from the three doses from baseline to day 56 of the trial. The release of the final top-line data for study contained efficacy data for just the largest 600 mg dose of VX-809 with Vertex highlighting the improvement in lung function from day 28 to 56.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription